Simultaneous quantitative analysis of ketanserin and ketanserinol in plasma by RP-HPLC with fluorescence detection

A sensitive and selective high-performance liquid chromatographic assay for the quantification of ketanserin and ketanserinol in human plasma was developed and validated. The procedure involves extraction of ketanserin and ketanserinol from plasma using an Extrelut NT-1 solid-phase extraction column. The chromatograph was equipped with a Hypersil BDS column (100 x 4.5 mm, 3 micro m particle size). Separation was performed with a mixture of acetate buffer 0.01 M, pH 4.9-methanol-acetonitrile (52:40:8, v/v/v). Detection was performed with fluorescence detection (lambda(ex) = 332 nm and lambda(em) = 410 nm). Calibration curves were linear (r(2) = 0.999) in the range 0-400 ng/mL for both ketanserin and ketanserinol. The repeatability coefficient for ketanserin and ketanserinol was 3.1 and 3.0%, respectively. The reproducibility coefficient for ketanserin and ketanserinol was 10.5 and 9.1%, respectively. The limit of quantification for both ketanserin and ketanserinol was 2.0 ng/mL. The mean recovery yield for both ketanserin and ketanserinol was 60%. In an 8 h work day approximately 60 samples, including calibration and reference standards, could be processed.     

Development and validation of an LC–MS/MS method for the quantification of artificial sweeteners in human matrices

Artificial sweeteners are widely used as substitutes for sugar. The sweeteners are generally considered safe, however their whereabouts during pregnancy and lactation and the effect on child development are poorly explored. There is a need for new tools to measure these substances during pregnancy and lactation. Here, we describe the development and validation of a sensitive liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of acesulfame, cyclamate, saccharin and sucralose in human plasma, umbilical cord blood, amniotic fluid and breast milk. The samples were prepared by protein precipitation and separated on a Luna Omega Polar C₁₈ column (2.1 × 50 mm, 1.6 μm). Electrospray ionization in negative mode and multiple reaction monitoring were used to monitor the ion transitions. The validated concentration ranges were from 1 to 500 ng/ml (10–500 ng/ml for sucralose). Interassay precisions were all ≤15% and the accuracies were within ±15%. Stability, linearity, dilution integrity, carryover and recovery were also examined and satisfied the validation criteria. Finally, this analytical method was successfully applied on spiked samples of plasma, umbilical cord blood, amniotic fluid and breast milk, proving its suitability for use in clinical studies on artificial sweeteners, including during pregnancy and lactation.     

Noninvasive prenatal paternity testing by maternal plasma DNA sequencing in twin pregnancies

SNPs, combined with massively parallel sequencing technology, have proven applicability in noninvasive prenatal paternity testing (NIPPT) for singleton pregnancies in our previous research, using circulating cell-free DNA in maternal plasma. However, the feasibility of NIPPT in twin pregnancies has remained uncertain. As a pilot study, we developed a practical method to noninvasively determine the paternity of twin pregnancies by maternal plasma DNA sequencing based on a massively parallel sequencing platform. Blood samples were collected from 15 pregnant women (twin pregnancies at 9–18 weeks of gestation). Parental DNA and maternal plasma cell-free DNA were analyzed with custom-designed probes covering 5226 polymorphic SNP loci. A mathematical model for data interpretation was established, including the zygosity determination and paternity index calculations. Each plasma sample was independently tested against the alleged father and 90 unrelated males. As a result, the zygosity in each twin case was correctly determined, prior to paternity analysis. Further, the correct biological father was successfully identified, and the paternity of all 90 unrelated males was excluded in each case. Our study demonstrates that NIPPT can be performed for twin pregnancies. This finding may contribute to development in NIPPT and diagnosis of certain genetic diseases.     

超促排卵治疗后卵泡破裂合并官外孕一例

一名继发不孕，多囊卵巢病史的妇女接受ＨＭＧ和ＨＣＧ超促排卵治疗后，发生了并发症，即卵泡破裂出血，宫外孕，卵巢过度刺激综合征等。提示进行超促卵治疗时，必须合理使用排卵药及加强监测手段，以促证治疗的安全性。     

妊娠晚期羊水中微量元素测定及其与胎儿生长发育关系的研究

对１０２名足月正常妊娠第一胎的产妇妊娠晚期羊水中６种微量元素（锌、铜、锰、铁、钙、镁）首次进行了测定，并通过对出生新生儿生长发育的监测探讨其与胎儿生长发育的关系。妊娠晚期羊水中６种微量元素含量（±Ｓ／×１０－５）分别为：Ｚｎ２．２９±１．７７，Ｃｕ０．１４±０．１４，Ｍｎ０．１３±０．２３，Ｆｅ３．６９±２．７０，Ｃａ８２．５４±７４．１８，Ｍｇ１８．７１±１１．０９．男女新生儿其母羊水中微量元素含量比较无显著差异，Ｐ≥０．０５．与文献报道中期妊娠羊水中所含微量元素比较有增加趋势．６种微量元素相互关系中．与锌、钙呈正相关外，锌与铜、锰、铁、镁呈负相关．低体重组与低身长组新生儿孕母羊水中锌含量明显低于高体重组和高身长组，有显著差异，Ｐ≤０．０１．铁在高身长组含量增高，与低身长组比较有显著差异，Ｐ≤０．０５．锰于低体重组含量升高，与高体重组比较有显著差异，Ｐ≤０．０１．镁与铜于低身长组含量升高，与高身长组比较有显著差异，Ｐ分别≤０．０５与０．０１．可见高铜、高锰、高镁可致胎儿生长发育迟缓．     

细菌性阴道病与甲硝唑治疗对妊娠结局的影响探讨

目的探讨细菌性阴道病和甲硝唑治疗对妊娠结局的影响。方法选取吉水县醪桥镇人口与计划生育服务所2014年7月至2015年7月收治的120例中晚期妊娠合并BV者,根据自愿原则分为治疗组和未治疗组(C组)。治疗组中口服用药为A组,阴道用药为B组。结果治疗组中两种不同用药方式都对妊娠合并BV患者有着显著的治疗效果,两组比较无统计学意义(P0.05);治疗组妊娠结局总不良率仅为10%,未治疗组中总不良率高达73.3%,对比差距显著,具备统计学意义(P0.05)。结论对妊娠期合并细菌性阴道病妇女使用甲硝唑治疗,对提升妊娠期妇女生活品质和降低不良妊娠风险有着关键的作用,同时具有十分重要的参考意义。     

Determination of the transplacental transfer of paclitaxel and antipyrine by high performance liquid chromatography coupled with photodiode array detector

Ex vivo placental perfusion experiments are important in understanding the quantity and mechanisms of xenobiotic transport to the fetus during pregnancy. Our study demonstrates that paclitaxel and antipyrine concentrations in placental perfusion medium containing physiological concentrations of human serum albumin during pregnancy (30?mg/mL) can be quantified by RP-HPLC and UV detection. A liquid-liquid extraction method was developed for the quantification of paclitaxel and celecoxib (internal standard) from perfusion medium. Antipyrine, which is a necessary marker in placental perfusions for determining the validity of experiments and calculating the clearance index of xenobiotics, was also analyzed by HPLC and UV detection. Antipyrine concentrations were determined by HPLC after precipitating the perfusion medium in acetonitrile and separating the precipitated proteins by centrifugation. Concentrations were fitted to linear regressions with R² values approaching 1. Lower limits of detection for paclitaxel and antipyrine were 100?ng/mL and 200?ng/mL, respectively. Both methods demonstrated high intra-day and inter-day precision and trueness. Additionally, the use of these methods was demonstrated in a placental perfusion experiment using Taxol^® (paclitaxel dissolved in Cremophor-EL). The fetal transfer rate of Taxol was 6.6% after 1 hour.     

Synthesis and Pregnancy Terminating Activity of 2-Aryl imidazo [2,1-a] isoquinolines

Several kinds of potential pregnancy terminating agents have been identified such as 2-aryl pyrazolo [5,1-a] isoindoles and isoquinolines1, pyrazolo[1,5-a] indoles and quinolines2, 3,5-diaryl-s-triazoles3, 2-phenyl triazole, pyrozole, imidazole isoindoles and homologues4 etc. In order to investigate their structure-activity relationship, the quantitative structure-activity relationship (QSAR) of 2-aryl imidazo [2,1-a] isoquinolines5 has been studied with multiple regression and BP Artificial…     

孕鼠胎盘膜对混合稀土常乐的屏障作用

为评估混合稀土常乐对人体胚胎的潜在危害, 在光镜和电镜下观察了混合稀土常乐染毒后的胎盘组织, 以了解其在胎盘组织中的存在形式和分布情况, 同时应用电感耦合等离子体质谱法(ICP-MS)检测染毒后的孕鼠血清、胚胎组织提取液和羊水中的稀土含量以确定其能否通过胎盘屏障. 染毒于雌鼠妊娠第六天开始, 每天分别以0.3, 2, 5和20 mg·kg-1混合稀土常乐灌胃, 直至妊娠第十八天. 结果显示: 光镜下, 染毒组胎盘绒毛中毛细血管周围合体细胞滋养层胞质内积聚有许多圆形黑色细小颗粒, 颗粒的多少与染毒剂量呈正相关; 电镜下, 染毒组胎盘绒毛中可见有膜包裹的致密体及合体细胞滋养层细胞内线粒体有不同程度的空泡变和嵴断裂; ICP-MS检测: 孕鼠血清铈的含量随染毒剂量的增加而递增, 染毒组胎儿羊水和孕鼠血清中稀土总量, 只有20 mg·kg-1组与对照组相比有显著增加, 其余各组均无显著差异. 胚胎组织提取液中各组的稀土总含量没有变化. 由此得出结论: 胎盘膜对混合稀土常乐进入胚体有很大的限制作用, 但是, 当混合稀土常乐在胎盘膜中积累增加到一定程度时, 可少量透过胎盘屏障, 进入胚体.